デフォルト表紙
市場調査レポート
商品コード
968265

世界の腫瘍溶解性ウイルス免疫療法の市場規模調査:タイプ別、用途別および地域別予測(2020年~2027年)

Global Oncolytic Virus Immunotherapy Market Size study, by Type (Engineering Oncolytic Viruses and Wild-Type Oncolytic Viruses), By Application (Hospitals, Clinics and Ambulatory Surgical Centers) and Regional Forecasts 2020-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.66円
世界の腫瘍溶解性ウイルス免疫療法の市場規模調査:タイプ別、用途別および地域別予測(2020年~2027年)
出版日: 2020年10月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腫瘍溶解性ウイルス免疫療法の市場規模は2019年に約6,890万米ドルであり、2020年から2027年の予測期間にわたって12.00%を超える成長率で成長すると予想されています。医学と技術の進歩により、腫瘍溶解性ウイルス免疫療法は一貫した成長を遂げています。免疫系を含む腫瘍生物学の3層を主に対象とする一連の免疫療法は、有望な最終結果によりかなりの牽引力を獲得しています。腫瘍溶解性ウイルス免疫療法を用いた初期段階の臨床試験中の有望な結果は、市場の全体的な成長を後押しする上で不可欠な役割を果たしています。進行中の臨床試験では、腫瘍溶解性ウイルス免疫療法の進歩と腫瘍溶解性ウイルス免疫療法への規制措置により、2020年から2027年の予測期間中に市場の成長が促進されます。ただし、臨床開発の後期段階での失敗は、2020年から2027年の予測期間中に市場の成長を妨げる可能性があります。

当レポートでは、腫瘍溶解性ウイルス免疫療法市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・用途別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の腫瘍溶解性ウイルス免疫療法市場の定義と範囲

第3章 世界の腫瘍溶解性ウイルス免疫療法市場力学

  • 腫瘍溶解性ウイルス免疫療法市場の影響分析

第4章 世界の腫瘍溶解性ウイルス免疫療法市場:業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論

第5章 世界の腫瘍溶解性ウイルス免疫療法市場:タイプ別

  • 市場スナップショット
  • 世界の腫瘍溶解性ウイルス免疫療法市場-潜在的な分析
  • 世界の腫瘍溶解性ウイルス免疫療法市場
  • 腫瘍溶解性ウイルス免疫療法市場:サブセグメント分析
    • 腫瘍溶解性エンジニアリングウイルス
    • 腫瘍溶解性野生型ウイルス

第6章 世界の腫瘍溶解性ウイルス免疫療法市場:アプリケーション別

  • 市場スナップショット
  • 世界の腫瘍溶解性ウイルス免疫療法市場-潜在的な分析
  • 世界の腫瘍溶解性ウイルス免疫療法市場:推定と予測
  • 腫瘍溶解性ウイルス免疫療法市場:サブセグメント分析
    • 病院
    • クリニック
    • 外来手術センター

第7章 世界の腫瘍溶解性ウイルス免疫療法市場:地域別分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第8章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Merck
    • Amgen
    • TILT Biotherapeutics
    • Oncorus
    • Sorrento Therapeutics
    • Shanghai Sunway Biotech
    • BioVex, Inc.
    • Cold Genesys, Inc.
    • DNAtrix Therapeutics
    • Genelux Corporation

第9章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Oncolytic Virus Immunotherapy market, report scope
  • TABLE 2. Global Oncolytic Virus Immunotherapy market estimates & forecasts by region 2017-2027 (USD Million)
  • TABLE 3. Global Oncolytic Virus Immunotherapy market estimates & forecasts by Type 2017-2027 (USD Million)
  • TABLE 4. Global Oncolytic Virus Immunotherapy market estimates & forecasts by Application 2017-2027 (USD Million)
  • TABLE 5. Global Oncolytic Virus Immunotherapy market by segment, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 6. Global Oncolytic Virus Immunotherapy market by region, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 7. Global Oncolytic Virus Immunotherapy market by segment, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 8. Global Oncolytic Virus Immunotherapy market by region, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 9. Global Oncolytic Virus Immunotherapy market by segment, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 10. Global Oncolytic Virus Immunotherapy market by region, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 11. Global Oncolytic Virus Immunotherapy market by segment, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 12. Global Oncolytic Virus Immunotherapy market by region, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 13. Global Oncolytic Virus Immunotherapy market by segment, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 14. Global Oncolytic Virus Immunotherapy market by region, estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 15. U.S. Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 16. U.S. Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 17. U.S. Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 18. U.S. Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 19. Canada Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 20. Canada Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 21. Canada Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 22. Canada Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 23. UK Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 24. UK Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 25. UK Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 26. UK Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 27. Germany Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 28. Germany Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 29. Germany Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 30. Germany Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 31. France Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 32. France Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 33. France Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 34. France Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 35. Spain Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 36. Spain Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 37. Spain Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 38. Spain Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 39. Italy Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 40. Italy Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 41. Italy Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 42. Italy Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 43. ROE Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 44. ROE Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 45. ROE Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 46. ROE Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 47. China Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 48. China Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 49. China Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 50. China Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 51. India Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 52. India Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 53. India Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 54. India Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 55. Japan Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 56. Japan Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 57. Japan Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 58. Japan Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 59. Australia Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 60. Australia Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 61. Australia Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 62. Australia Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 63. South Korea Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 64. South Korea Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 65. South Korea Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 66. South Korea Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 67. ROPAC Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 68. ROPAC Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 69. ROPAC Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 70. ROPAC Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 71. Brazil Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 72. Brazil Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 73. Brazil Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 74. Brazil Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 75. Mexico Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 76. Mexico Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 77. Mexico Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 78. Mexico Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 79. ROLA Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 80. ROLA Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 81. ROLA Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 82. ROLA Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 83. ROW Oncolytic Virus Immunotherapy market estimates & forecasts, 2017-2027 (USD Million)
  • TABLE 84. ROW Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 85. ROW Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 86. ROW Oncolytic Virus Immunotherapy market estimates & forecasts by segment 2017-2027 (USD Million)
  • TABLE 87. List of secondary sources, used in the study of global Oncolytic Virus Immunotherapy market
  • TABLE 88. List of primary sources, used in the study of global Oncolytic Virus Immunotherapy market
  • TABLE 89. Years considered for the study
  • TABLE 90. Exchange rates considered

LIST OF FIGURES

  • FIG 1. Global Oncolytic Virus Immunotherapy market, research methodology
  • FIG 2. Global Oncolytic Virus Immunotherapy market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Oncolytic Virus Immunotherapy market, key trends 2019
  • FIG 5. Global Oncolytic Virus Immunotherapy market, growth prospects 2020-2027
  • FIG 6. Global Oncolytic Virus Immunotherapy market, porters 5 force model
  • FIG 7. Global Oncolytic Virus Immunotherapy market, pest analysis
  • FIG 8. Global Oncolytic Virus Immunotherapy market, value chain analysis
  • FIG 9. Global Oncolytic Virus Immunotherapy market by segment, 2017 & 2027 (USD Million)
  • FIG 10. Global Oncolytic Virus Immunotherapy market by segment, 2017 & 2027 (USD Million)
  • FIG 11. Global Oncolytic Virus Immunotherapy market by segment, 2017 & 2027 (USD Million)
  • FIG 12. Global Oncolytic Virus Immunotherapy market by segment, 2017 & 2027 (USD Million)
  • FIG 13. Global Oncolytic Virus Immunotherapy market by segment, 2017 & 2027 (USD Million)
  • FIG 14. North America Oncolytic Virus Immunotherapy market 2017 & 2027 (USD Million)
  • FIG 15. Europe Oncolytic Virus Immunotherapy market 2017 & 2027 (USD Million)
  • FIG 16. Asia Pacific Oncolytic Virus Immunotherapy market 2017 & 2027 (USD Million)
  • FIG 17. Latin America Oncolytic Virus Immunotherapy market 2017 & 2027 (USD Million)
  • FIG 18. Global Oncolytic Virus Immunotherapy market, company market share analysis (2019)
目次

Global Oncolytic Virus Immunotherapy Market is valued approximately USD 68.90 million in 2019 and is anticipated to grow with a healthy growth rate of more than 12.00 % over the forecast period 2020-2027. Due to advancements in medical science and technology, immunotherapy is at the helm of modern oncology care due to which the deployment of oncolytic virus immunotherapy has witnessed consistent growth. A spectrum of immunotherapies that primarily target three layers of tumor biology, including immune system and it has gained considerable traction owing to the promising end-results. Further, the development of anti-cancer treatment therapies has largely focused on delivering customized therapy to cellular targets. The promising outcomes during the early stage clinical trials with oncolytic virus immunotherapy is further expected to play an imperative tole in boosting the overall growth of the market. Also, the key players are focusing on strategies such as product launch, innovation and merger & acquisition to sustain themselves amidst fierce competition. Ongoing clinical trials, advancement in oncolytic virus immunotherapy along with the regulatory imposition on oncolytic virus immunotherapy would drive the growth of the market during the forecast period of 2020-2027. However, failure of these molecules in late stage of clinical developments may be leveling off for companies operating in the market which is hampering the growth of the market during the forecast period of 2020-2027.

The regional analysis of global Oncolytic Virus Immunotherapy market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region due to the owing to high prevalence of cancer, specifically melanoma cancer. Also, the dominance of the region is witnessed owing to the strong presence of leading manufacturers and high rate of manufacturer's sponsorship are contributing to greater availability of oncolytic virus immunotherapy in the region. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:

Merck

Amgen

TILT Biotherapeutics

Oncorus

Sorrento Therapeutics

Shanghai Sunway Biotech

BioVex, Inc.

Cold Genesys, Inc.

DNAtrix Therapeutics

Genelux Corporation

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Engineering Oncolytic Viruses

Wild-Type Oncolytic Viruses

By Application:

Hospitals

Clinics

Ambulatory Surgical Centers

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Oncolytic Virus Immunotherapy Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Million)
    • 1.2.1. Oncolytic Virus Immunotherapy Market, by Region, 2018-2027 (USD Million)
    • 1.2.2. Oncolytic Virus Immunotherapy Market, by Type 2018-2027 (USD Million)
    • 1.2.3. Oncolytic Virus Immunotherapy Market, by Application 2018-2027 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Oncolytic Virus Immunotherapy Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Oncolytic Virus Immunotherapy Market Dynamics

  • 3.1. Oncolytic Virus Immunotherapy Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Oncolytic Virus Immunotherapy Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Oncolytic Virus Immunotherapy Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Oncolytic Virus Immunotherapy Market by Type, Performance - Potential Analysis
  • 5.3. Global Oncolytic Virus Immunotherapy Market Estimates & Forecasts by Type 2017-2027 (USD Million)
  • 5.4. Oncolytic Virus Immunotherapy Market, Sub Segment Analysis
    • 5.4.1. Engineering Oncolytic Viruses
    • 5.4.2. Wild-Type Oncolytic Viruses

Chapter 6. Global Oncolytic Virus Immunotherapy Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Oncolytic Virus Immunotherapy Market by Application, Performance - Potential Analysis
  • 6.3. Global Oncolytic Virus Immunotherapy Market Estimates & Forecasts by Application 2017 -2027 (USD Million)
  • 6.4. Oncolytic Virus Immunotherapy Market, Sub Segment Analysis
    • 6.4.1. Hospitals
    • 6.4.2. Clinics
    • 6.4.3. Ambulatory Surgical Centers

Chapter 7. Global Oncolytic Virus Immunotherapy Market, Regional Analysis

  • 7.1. Oncolytic Virus Immunotherapy Market, Regional Market Snapshot
  • 7.2. North America Oncolytic Virus Immunotherapy Market
    • 7.2.1. U.S. Oncolytic Virus Immunotherapy Market
      • 7.2.1.1. Type breakdown estimates & forecasts, 2017-2027
      • 7.2.1.2. Application breakdown estimates & forecasts, 2017-2027
    • 7.2.2. Canada Oncolytic Virus Immunotherapy Market
  • 7.3. Europe Oncolytic Virus Immunotherapy Market Snapshot
    • 7.3.1. U.K. Oncolytic Virus Immunotherapy Market
    • 7.3.2. Germany Oncolytic Virus Immunotherapy Market
    • 7.3.3. France Oncolytic Virus Immunotherapy Market
    • 7.3.4. Spain Oncolytic Virus Immunotherapy Market
    • 7.3.5. Italy Oncolytic Virus Immunotherapy Market
    • 7.3.6. Rest of Europe Oncolytic Virus Immunotherapy Market
  • 7.4. Asia-Pacific Oncolytic Virus Immunotherapy Market Snapshot
    • 7.4.1. China Oncolytic Virus Immunotherapy Market
    • 7.4.2. India Oncolytic Virus Immunotherapy Market
    • 7.4.3. Japan Oncolytic Virus Immunotherapy Market
    • 7.4.4. Australia Oncolytic Virus Immunotherapy Market
    • 7.4.5. South Korea Oncolytic Virus Immunotherapy Market
    • 7.4.6. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market
  • 7.5. Latin America Oncolytic Virus Immunotherapy Market Snapshot
    • 7.5.1. Brazil Oncolytic Virus Immunotherapy Market
    • 7.5.2. Mexico Oncolytic Virus Immunotherapy Market
  • 7.6. Rest of The World Oncolytic Virus Immunotherapy Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. Merck
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Amgen
    • 8.2.3. TILT Biotherapeutics
    • 8.2.4. Oncorus
    • 8.2.5. Sorrento Therapeutics
    • 8.2.6. Shanghai Sunway Biotech
    • 8.2.7. BioVex, Inc.
    • 8.2.8. Cold Genesys, Inc.
    • 8.2.9. DNAtrix Therapeutics
    • 8.2.10. Genelux Corporation

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption